Aravive Investor Presentation Deck
P1b ccRCC: Pretreatment Serum SAXL/GAS6 is a Potential
Biomarker with 100% Negative Predictability
PR for Patients with low SAXL/GAS6
Confirmed PR for Patients with high
SAXL/GAS6
9-month Progression-Free Survival in
Biomarker High subgroup
All P1b Patients
(n=25) 1
0/5 (0%)
11/20 (55%)
72%
Best Response
P1b 15 mg/kg
(n=16)
0/4 (0%)
8/12 (67%) 2
73%
P1b 20 mg/kg
(n=9) 1
0/1 (0%)
3/8 (38%)
73%
Exact biomarker threshold to be determined once all data analyzed
1 One 20 mg/kg patient in Ph 1b does not have ratio value
2 One additional biomarker high patient had an initial PR but then PD on the subsequent scan so is captured as PD
Note: Confirmed objective response rate for (60mg) cabozantinib from METEOR and CANTATA studies was 17% and 28%; Median
PFS for (60mg) was 7.4 and 9.3 months; 9-month PFS 36% and 50%
Data cutoff August 8, 2022View entire presentation